The heart failure drugs market industry is projected to grow from significant value by 2032, exhibiting a compound annual growth rate (CAGR) of 17.00% during the forecast period (2023 - 2032). Increasing prevalence of heart failure, technological advancements, and the increasing healthcare expenditure are the main market drivers anticipated to propel the heart failure drugs market in the UK.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The increasing prevalence of heart failure in the UK is a major factor driving the growth of the heart failure drugs market. As the number of people living with heart failure increases, there is a growing demand for effective treatments and therapies that can help manage the symptoms of the disease and improve patients' quality of life. The aging population in the UK is a key factor contributing to the increased prevalence of heart failure. As people age, their risk of developing heart failure increases, and the number of elderly people in the UK is growing. This has led to an increase in the overall prevalence of heart failure in the country.
In addition, there has been a rise in the incidence of cardiovascular diseases in the UK, which is a major risk factor for heart failure. Factors such as obesity, smoking, and a sedentary lifestyle are contributing to the increased incidence of cardiovascular diseases in the UK population. Advances in medical technology and treatments have allowed people with heart disease to live longer, which means that more people are living with heart failure. This has increased the overall prevalence of heart failure in the UK.
Increasing healthcare expenditure is another important driver of growth in the UK heart failure drugs market. As the demand for heart failure drugs and treatments increases, healthcare expenditure is rising to meet this demand. The UK government is committed to improving healthcare services and increasing access to healthcare for all citizens. This includes investment in healthcare infrastructure, research and development, and access to healthcare services. The government has also launched initiatives to improve the diagnosis and management of heart failure, which has contributed to the growth of the heart failure drugs market.
The National Health Service (NHS) in the UK plays a crucial role in providing healthcare services to the population. The NHS is funded by the government and provides free healthcare services to all citizens. As the demand for heart failure drugs and treatments increases, the NHS is investing more resources in this area to meet the growing demand. In addition, private healthcare providers are also investing in the heart failure drugs market in the UK. Private healthcare providers offer a range of services, including specialist consultations, diagnostic tests, and advanced treatments for heart failure. As more people seek private healthcare services, there is a growing demand for heart failure drugs and treatments in this sector.
The UK Heart Failure Drugs market segmentation, based on type includes ACE Inhibitors, Angiotensin Receptor Blockers, Beta Blocker, Diuretics, and Others. The ACE Inhibitors segment dominated the market mostly. They are commonly prescribed to patients with heart failure, and are considered to be one of the most effective treatments for this condition. They work by blocking the production of a hormone called angiotensin II, which can cause blood vessels to narrow and increase blood pressure. This helps to reduce the workload on the heart and improve blood flow to the body's organs and tissues.
The UK Heart Failure Drugs market segmentation, based on application, includes Injection, Capsule, and Tablets. The tablets category generated the most income. They are commonly prescribed form of medication for heart failure, as they are easy to take, convenient to store, and can be taken with or without food. Tablets are available in a variety of strengths and formulations, which allows healthcare providers to tailor the dosage to the patient's specific needs. They are also available in both branded and generic forms, which makes them more affordable and accessible to a wider range of patients.
The UK Heart Failure Drugs market segmentation, based on distribution channel, includes Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. The hospital pharmacies category generated the most income. Hospital pharmacies are the primary source of heart failure drugs in the UK, as they are responsible for dispensing medications to patients who are being treated in hospital settings. Heart failure is a serious medical condition that often requires hospitalization, particularly in cases where the patient's symptoms are severe. In these cases, hospital pharmacies are responsible for providing the medications that are needed to manage the patient's condition.
The UK Heart Failure Drugs market segmentation, based on end users, includes Hospitals, Specialty Centres, and Others. The hospitals category dominated the market. Hospitals are the primary location where patients with heart failure are diagnosed, treated, and monitored. As a result, hospitals are responsible for the majority of heart failure drug prescriptions in the UK. Hospitals have access to specialist physicians and healthcare professionals who are trained in the diagnosis and treatment of heart failure. They also have the necessary equipment and facilities to provide advanced treatments for heart failure, including surgery and implantable devices.
Figure 1: UK Heart Failure Drugs Market, by End Users, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The UK Heart Failure Drugs Market is expected to continue to grow in the coming years, driven by a combination of factors including increasing prevalence of heart failure, an aging population, and advances in medical technology and treatments. The prevalence of heart failure is increasing in the UK, driven by factors such as an aging population and the rising incidence of risk factors such as obesity and diabetes. As a result, there is a growing demand for heart failure drugs in the UK.
The UK government has launched a number of initiatives aimed at improving the diagnosis and management of heart failure. These initiatives include the development of clinical guidelines for the treatment of heart failure, as well as investment in research and development of new drugs and therapies. In addition, the UK has a well-developed healthcare infrastructure, which includes a national health service (NHS) that provides free healthcare services to all citizens. As a result, patients with heart failure have access to a range of treatments and medications, regardless of their ability to pay.
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the heart failure drugs market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, heart failure drugs industry must offer cost-effective items.
Major players in the heart failure drugs market are attempting to increase market demand by investing in research and development operations includes Amgen Inc. (U.K.); AstraZeneca (U.K.); Bayer AG (U.K.); Novartis AG (U.K.); Gilead Sciences, Inc (U.K.); GlaxoSmithKline plc (U.K.); Pfizer Inc. (U.K.); Teva Pharmaceutical Industries Ltd (U.K.); Boehringer Ingelheim International GmbH (U.K.); Actelion Pharmaceuticals Ltd (U.K.); Bristol-Myers Squibb Company (U.K.); CYTOKINETICS, INC. (U.K.); Eli Lilly and Company (U.K.).
Key Companies in the Heart Failure Drugs Market Include
Heart Failure Drugs Industry Developments
2020: Mylan and Upjohn completed their merger to form Viatris, a global pharmaceutical company with a strong presence in the UK Heart Failure Drugs Market.
2021: Pfizer completed its acquisition of Amplyx Pharmaceuticals, which includes a portfolio of antifungal drugs. While not directly related to heart failure, this acquisition expands Pfizer's presence in the broader pharmaceutical market.
| Report Attribute/Metric | Details |
| Market Size 2022 | Significant value |
| Market Size 2023 | Significant value |
| Market Size 2032 | Significant value |
| Compound Annual Growth Rate (CAGR) | 17.00% (2023-2032) |
| Base Year | 2022 |
| Market Forecast Period | 2023-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, Application, Distribution Channel, End Users, and Region |
| Countries Covered | UK |
| Key Companies Profiled | Amgen Inc. (U.K.); AstraZeneca (U.K.); Bayer AG (U.K.); Novartis AG (U.K.); Gilead Sciences, Inc (U.K.); GlaxoSmithKline plc (U.K.); Pfizer Inc. (U.K.); Teva Pharmaceutical Industries Ltd (U.K.); Boehringer Ingelheim International GmbH (U.K.); Actelion Pharmaceuticals Ltd (U.K.); Bristol-Myers Squibb Company (U.K.); CYTOKINETICS, INC. (U.K.); Eli Lilly and Company (U.K.) |
| Key Market Opportunities | ·      Strategic alliance between healthcare providers ·      Rise in the number of new investors, and robust R&D efforts by current market participants |
| Key Market Dynamics | ·      Increasing prevalence of heart failure ·      Advancements in medical technology and treatments |
Frequently Asked Questions (FAQ) :
The UK heart failure drugs market size was valued at Significant value in 2022.
The market is projected to grow at a CAGR of 17.00% during the forecast period, 2023-2032.
The key players in the market are Amgen Inc. (U.K.); AstraZeneca (U.K.); Bayer AG (U.K.); Novartis AG (U.K.); Gilead Sciences, Inc (U.K.); GlaxoSmithKline plc (U.K.); Pfizer Inc. (U.K.); Teva Pharmaceutical Industries Ltd (U.K.); Boehringer Ingelheim International GmbH (U.K.); Actelion Pharmaceuticals Ltd (U.K.); Bristol-Myers Squibb Company (U.K.); CYTOKINETICS, INC. (U.K.); Eli Lilly and Company (U.K.).
The ACE Inhibitors category dominated the market in 2022.
The hospital pharmacies category had the largest share in the market.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
